Aligos Grants 10,700 Stock Options to New Employees
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 24 2026
0mins
Should l Buy ALGS?
Source: Newsfilter
- Stock Option Grant: Aligos Therapeutics granted 10,700 non-qualified stock options to new employees on April 22, 2026, aimed at attracting top talent and enhancing employee loyalty, thereby strengthening the company's competitive position in the biopharmaceutical sector.
- Grant Plan Context: The stock option grant was made under Aligos' 2024 Inducement Plan, which is exclusively used for awarding equity to individuals not previously employed by the company, complying with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price Setting: The exercise price for the granted stock options is set equal to the closing price of Aligos' common stock on the grant date, ensuring alignment of interests between new employees and shareholders, which promotes long-term value enhancement for the company.
- Vesting Arrangement: The stock options will vest over four years, with 25% vesting on the first anniversary and the remainder vesting in equal monthly installments, a structure designed to incentivize long-term employee retention and contributions to the company's ongoing growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALGS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALGS
Wall Street analysts forecast ALGS stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.030
Low
20.00
Averages
81.67
High
175.00
Current: 6.030
Low
20.00
Averages
81.67
High
175.00
About ALGS
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aligos Therapeutics Q1 Earnings Beat Expectations
- Strong Earnings Report: Aligos Therapeutics reported a Q1 GAAP EPS of -$2.21, beating expectations by $0.04, indicating an improvement in financial performance that may boost investor confidence.
- Significant Revenue Growth: The company achieved revenue of $2.83M, representing an 812.9% year-over-year increase, exceeding expectations by $2.5M, which highlights strong product demand and significant future growth potential.
- Cash Flow Status: As of March 31, 2026, cash, cash equivalents, and investments totaled $54.9 million, down from $77.8 million as of December 31, 2025; however, this is expected to fund operations into Q4 2026, ensuring financial sustainability.
- Strategic Partnership Opportunity: The anticipated $25M upfront payment from the Amoytop Greater China licensing deal is expected to provide additional funding support, further advancing the company's efforts in hepatitis B drug development.
See More
Aligos Therapeutics Grants Stock Options to New Employees
- Stock Options Granted: Aligos Therapeutics has granted 10,700 stock options to new employees under Nasdaq Listing Rule 5635(c)(4), aimed at attracting talent and supporting the company's advancement in therapies for liver and viral diseases.
- Incentive Plan Details: The non-qualified stock options have an exercise price equal to the closing price on the grant date and will vest over four years, with 25% vesting on the first anniversary and the remainder in equal monthly installments, contingent on continued employment.
- Market Performance: Over the past year, ALGS shares have traded between $4.20 and $13.69, currently priced at $6.53, reflecting a 6.49% increase, indicating positive market sentiment towards the company's prospects.
- Strategic Implications: The stock option grants not only enhance employee retention but also demonstrate Aligos' commitment to advancing its pipeline targeting chronic hepatitis B, MASH, obesity, and coronaviruses.
See More
Aligos Grants 10,700 Stock Options to New Employees
- Stock Option Grant: Aligos Therapeutics granted 10,700 non-qualified stock options to new employees on April 22, 2026, aimed at attracting top talent and enhancing employee loyalty, thereby strengthening the company's competitive position in the biopharmaceutical sector.
- Grant Plan Context: The stock option grant was made under Aligos' 2024 Inducement Plan, which is exclusively used for awarding equity to individuals not previously employed by the company, complying with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price Setting: The exercise price for the granted stock options is set equal to the closing price of Aligos' common stock on the grant date, ensuring alignment of interests between new employees and shareholders, which promotes long-term value enhancement for the company.
- Vesting Arrangement: The stock options will vest over four years, with 25% vesting on the first anniversary and the remainder vesting in equal monthly installments, a structure designed to incentivize long-term employee retention and contributions to the company's ongoing growth.
See More
Aligos Licenses Hepatitis B Drug to Xiamen Amoytop, Secures $25M Upfront
- Deal Details: Aligos has signed a licensing agreement with Xiamen Amoytop, receiving an upfront payment of $25 million and the potential to earn up to $420 million in milestone payments, highlighting the company's prospects in hepatitis B treatment.
- Market Impact: The agreement led to a nearly 20% surge in Aligos shares during pre-market trading, and if sustained, it would mark the largest intraday gain since May 12, 2025, reflecting investor optimism about the company's future.
- Funding Support: Aligos expects that this deal will allow its current cash and investments to support operations into the fourth quarter of 2026, ensuring sufficient funding for future R&D and commercialization efforts.
- Market Opportunity: The drug targets over 90 million chronic hepatitis B patients in Greater China, and the combination with Amoytop's PEGBING® could offer more personalized treatment options, further expanding market share.
See More
Aligos Enters Exclusive Licensing Agreement with Xiamen Amoytop Biotech
- Exclusive Licensing Agreement: Aligos Therapeutics has signed an exclusive licensing agreement with Xiamen Amoytop Biotech Co., Ltd. to develop and commercialize pevifoscorvir sodium for chronic hepatitis B virus infection across Greater China, marking a strategic move into this significant market.
- Substantial Milestone Payments: Under the terms of the agreement, Aligos will receive an upfront milestone payment of $25 million, with the potential to earn up to $420 million in additional development, regulatory, and commercial milestone payments, highlighting the economic potential of this collaboration.
- Market Responsibility Transfer: Amoytop Biotech will take on the responsibility for development and commercialization in Greater China, while Aligos retains rights to the drug in major markets such as the U.S., Europe, Japan, and South Korea, optimizing resource allocation and market strategy.
- Cost Reduction in Development: This collaboration not only helps Aligos reduce development costs but also extends its financial runway, particularly against the backdrop of a large hepatitis B patient population in Greater China, which presents significant market potential and strategic importance.
See More
Aligos Enters Exclusive License Agreement with Amoytop
- Significant Agreement Value: Aligos has entered into an exclusive licensing agreement with Xiamen Amoytop Biotech Co., Ltd., receiving an upfront payment of $25 million and the potential for up to $420 million in clinical, regulatory, and sales milestone payments, indicating substantial financial upside from this deal.
- Market Potential: With over 90 million people living with HBV in Greater China, Amoytop's leadership in the region is expected to facilitate the development and regulatory success of pevifoscorvir sodium, thereby enhancing Aligos's market share in this critical area.
- Retention of Development Rights: Aligos retains development and commercialization rights in the U.S., Europe, South Korea, and Japan while also conducting clinical trials in Greater China, a strategy that will help maintain its competitive edge globally.
- Broad Collaboration Prospects: The partnership between Aligos and Amoytop is poised to not only advance the new drug's development but also potentially offer more personalized treatment options by combining it with Amoytop's PEGBING® therapy, further strengthening its market position in chronic HBV infection treatment.
See More
Aligos Therapeutics Q1 Earnings Beat Expectations
- Strong Earnings Report: Aligos Therapeutics reported a Q1 GAAP EPS of -$2.21, beating expectations by $0.04, indicating an improvement in financial performance that may boost investor confidence.
- Significant Revenue Growth: The company achieved revenue of $2.83M, representing an 812.9% year-over-year increase, exceeding expectations by $2.5M, which highlights strong product demand and significant future growth potential.
- Cash Flow Status: As of March 31, 2026, cash, cash equivalents, and investments totaled $54.9 million, down from $77.8 million as of December 31, 2025; however, this is expected to fund operations into Q4 2026, ensuring financial sustainability.
- Strategic Partnership Opportunity: The anticipated $25M upfront payment from the Amoytop Greater China licensing deal is expected to provide additional funding support, further advancing the company's efforts in hepatitis B drug development.
See More
Aligos Therapeutics Grants Stock Options to New Employees
- Stock Options Granted: Aligos Therapeutics has granted 10,700 stock options to new employees under Nasdaq Listing Rule 5635(c)(4), aimed at attracting talent and supporting the company's advancement in therapies for liver and viral diseases.
- Incentive Plan Details: The non-qualified stock options have an exercise price equal to the closing price on the grant date and will vest over four years, with 25% vesting on the first anniversary and the remainder in equal monthly installments, contingent on continued employment.
- Market Performance: Over the past year, ALGS shares have traded between $4.20 and $13.69, currently priced at $6.53, reflecting a 6.49% increase, indicating positive market sentiment towards the company's prospects.
- Strategic Implications: The stock option grants not only enhance employee retention but also demonstrate Aligos' commitment to advancing its pipeline targeting chronic hepatitis B, MASH, obesity, and coronaviruses.
See More
Aligos Grants 10,700 Stock Options to New Employees
- Stock Option Grant: Aligos Therapeutics granted 10,700 non-qualified stock options to new employees on April 22, 2026, aimed at attracting top talent and enhancing employee loyalty, thereby strengthening the company's competitive position in the biopharmaceutical sector.
- Grant Plan Context: The stock option grant was made under Aligos' 2024 Inducement Plan, which is exclusively used for awarding equity to individuals not previously employed by the company, complying with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price Setting: The exercise price for the granted stock options is set equal to the closing price of Aligos' common stock on the grant date, ensuring alignment of interests between new employees and shareholders, which promotes long-term value enhancement for the company.
- Vesting Arrangement: The stock options will vest over four years, with 25% vesting on the first anniversary and the remainder vesting in equal monthly installments, a structure designed to incentivize long-term employee retention and contributions to the company's ongoing growth.
See More
Aligos Licenses Hepatitis B Drug to Xiamen Amoytop, Secures $25M Upfront
- Deal Details: Aligos has signed a licensing agreement with Xiamen Amoytop, receiving an upfront payment of $25 million and the potential to earn up to $420 million in milestone payments, highlighting the company's prospects in hepatitis B treatment.
- Market Impact: The agreement led to a nearly 20% surge in Aligos shares during pre-market trading, and if sustained, it would mark the largest intraday gain since May 12, 2025, reflecting investor optimism about the company's future.
- Funding Support: Aligos expects that this deal will allow its current cash and investments to support operations into the fourth quarter of 2026, ensuring sufficient funding for future R&D and commercialization efforts.
- Market Opportunity: The drug targets over 90 million chronic hepatitis B patients in Greater China, and the combination with Amoytop's PEGBING® could offer more personalized treatment options, further expanding market share.
See More
Aligos Enters Exclusive Licensing Agreement with Xiamen Amoytop Biotech
- Exclusive Licensing Agreement: Aligos Therapeutics has signed an exclusive licensing agreement with Xiamen Amoytop Biotech Co., Ltd. to develop and commercialize pevifoscorvir sodium for chronic hepatitis B virus infection across Greater China, marking a strategic move into this significant market.
- Substantial Milestone Payments: Under the terms of the agreement, Aligos will receive an upfront milestone payment of $25 million, with the potential to earn up to $420 million in additional development, regulatory, and commercial milestone payments, highlighting the economic potential of this collaboration.
- Market Responsibility Transfer: Amoytop Biotech will take on the responsibility for development and commercialization in Greater China, while Aligos retains rights to the drug in major markets such as the U.S., Europe, Japan, and South Korea, optimizing resource allocation and market strategy.
- Cost Reduction in Development: This collaboration not only helps Aligos reduce development costs but also extends its financial runway, particularly against the backdrop of a large hepatitis B patient population in Greater China, which presents significant market potential and strategic importance.
See More
Aligos Enters Exclusive License Agreement with Amoytop
- Significant Agreement Value: Aligos has entered into an exclusive licensing agreement with Xiamen Amoytop Biotech Co., Ltd., receiving an upfront payment of $25 million and the potential for up to $420 million in clinical, regulatory, and sales milestone payments, indicating substantial financial upside from this deal.
- Market Potential: With over 90 million people living with HBV in Greater China, Amoytop's leadership in the region is expected to facilitate the development and regulatory success of pevifoscorvir sodium, thereby enhancing Aligos's market share in this critical area.
- Retention of Development Rights: Aligos retains development and commercialization rights in the U.S., Europe, South Korea, and Japan while also conducting clinical trials in Greater China, a strategy that will help maintain its competitive edge globally.
- Broad Collaboration Prospects: The partnership between Aligos and Amoytop is poised to not only advance the new drug's development but also potentially offer more personalized treatment options by combining it with Amoytop's PEGBING® therapy, further strengthening its market position in chronic HBV infection treatment.
See More
